KIR3DL1 and myeloid sarcoma: The scarce influence of HLA and KIR systems in this form of MS may at least partially explain why PPMS patients respond poorly to immunomodulatory therapy with corticosteroids and drugs such as glatiramer acetate or interferon-beta [36].